



3rd EU HCV Virtual Policy Summit Final Programme "Securing Wider EU Commitment to the elimination of HCV"

Wednesday, 24 March 2021

14:00 – 18:30 CET

**Meeting Chairs: Prof Angelos Hatzakis, Prof George Papatheodoridis and Prof Heiner Wedemeyer
Hepatitis B&C Public Policy Association**

| Timing | Programme Item | Speakers |
|----------------------|---|--|
| 14:00 – 14:25 | <p><u>Welcome and Introductory comments</u></p> <ul style="list-style-type: none"> • <i>Welcome and scene setting</i> <i>“5 years on: Revisiting the Elimination Manifesto”</i> • <i>Introductory comments on the continued need/opportunity to eliminate HCV in Europe</i> <ul style="list-style-type: none"> - <i>European Association for the Study of the Liver</i> - <i>ACHIEVE Coalition</i> - <i>WHO Europe</i> - <i>European Parliament</i> | <p>Prof Heiner Wedemeyer, Co-Chair HepBCPPA and Hannover Medical School, Germany</p> <p>Prof George Papatheodoridis, Co-chair HepBCPPA and University of Athens Medical School, Greece</p> <p>Prof Maria Buti, EU Policy Councillor, EASL</p> <p>Mr George Kalamitsis, Co-Chair ACHIEVE Coalition and Chair, Liver Patients International</p> <p>Dr Antons Mozalevskis, WHO Europe</p> <p>Mr Petros Kokkalis, MEP, Greece</p> |
| 14:25 – 14:55 | <p><u>Keynote addresses</u></p> <ul style="list-style-type: none"> • <i>How the EU can help deliver on the WHO elimination goal for viral Hepatitis B and C</i> • <i>The elimination of viral hepatitis as a public health threat in the EU : Keeping People Who Inject Drugs in focus</i> | <p><u>Chair:</u> Prof Rafael Esteban Mur Co-Chair HepBCPPA and University Hospital Vall d'Hebron, Barcelona, Spain</p> <p>Mr John F Ryan, Director of Public Health, Country Knowledge, Crisis Management, DG SANTE, European Commission</p> <p>Mr Alexis Goosdeel, Director, European Monitoring Centre for Drugs and Drug Addiction</p> |
| 14:55 – 15:40 | <p><u>Session 1. Progress in HCV elimination in Europe</u></p> <ul style="list-style-type: none"> • <i>Facts and figures of HCV elimination in Europe</i> | <p><u>Chairs:</u> Prof Massimo Colombo, San Raffaele Hospital, Milan, Italy</p> <p>Prof Markus Peck-Radosavljevic, Klinikum Klagenfurt, Klagenfurt, Austria</p> <p>Dr Homie Razavi, Centre for Disease Analysis, USA</p> |

| | | |
|---------------|--|--|
| | <ul style="list-style-type: none"> • <i>Care continuum and barriers</i> • <i>Synergies of harm reduction and HCV elimination</i> • <i>Panel discussion and Q&A moderated by session chairs</i> | <p>Prof Jeffrey Lazarus, ISGlobal, Barcelona, Spain Prof Sharon Hutchinson, Glasgow Caledonian University, Glasgow, UK</p> |
| 15:40 – 16:25 | <p>Session 2. HCV diagnosis in the era of HCV elimination</p> <ul style="list-style-type: none"> • <i>Screening of the general population</i> • <i>Diagnosing the risk groups – the hidden and mobile population</i> • <i>From evidence to impact: reaching the elimination targets in the EU/EEA</i> • <i>Panel discussion and Q&A moderated by session chairs</i> | <p>Chairs: Mr Bertrand Audoin International Association of Providers of AIDS Care Prof Nurdan Tözün, Acıbadem University School of Medicine, Turkey</p> <p>Prof Stanislas Pol, Hôpital Cochin, Université Sorbonne, Paris, France.</p> <p>Dr Ruth Zimmermann, Robert Koch Institute Berlin, Germany</p> <p>Dr Lina Nerlander, European Centre for Disease Prevention and Control</p> |
| 16:25 – 16:45 | <p>Session 3. COVID-19 and HCV</p> <ul style="list-style-type: none"> • <i>Impact of COVID-19 on HCV elimination</i> • <i>Q&A</i> | <p>Chair: Prof Harry LA Janssen, Toronto Western and Toronto General Hospital, University Health Network, Toronto, Canada</p> <p>Prof Alessio Aghemo, Humanitas University Hospital, Milan, Italy</p> |
| 16:45 – 16:50 | <p>Session 4a. Introduction to breakout sessions on Best Practices at the National level (PLENARY SESSION BEFORE BREAKOUT)</p> <ul style="list-style-type: none"> • <i>Introduction to breakout sessions</i> | <p>Chair: Prof Mojca Maticic, University Medical Centre Ljubljana, Slovenia</p> |
| 16:50 – 17:30 | <p>Session 4b. Elements of an effective elimination strategy - Best Practices at the National level (4 BREAKOUT SESSIONS – see details below)</p> <p><i>Breakout Session A. ACHIEVE Coalition - COVID -19 – lessons learnt for the elimination of viral hepatitis</i> <i>Breakout Session B. National Elimination Plans</i> <i>Breakout Session C. Best practice case studies from Ireland, Greece, Portugal and Montenegro</i> <i>Breakout Session D. Best practice case studies from Spain, Italy, Romania and Egypt</i></p> | <p>Breakout sessions</p> |

| | | |
|--------------------------|---|---|
| <p>17:30 – 18:20</p> | <p><u>Session 5. What political response/leadership?</u></p> <ul style="list-style-type: none"> • <i>EU4Health-funded network of Excellence</i> • <i>The role of European cities to eliminate HCV</i> • <i>EU for Health 2021: HCV elimination will reduce cancer</i> • <i>Presentation of Call to Action</i> • <i>Panel discussion and Q&A moderated by session chairs</i> | <p><u>Chairs:</u> Dr Ricardo Baptista-Leite MP UNITE, Global Parliamentarians Network to End Infectious Diseases Dr Manuel Carballo, International Centre for Migration, Health and Development, Switzerland</p> <p>Dr Cristian-Silviu Buşoi, MEP, Romania</p> <p>Mr Kostas Bakoyannis, Mayor of Athens, Greece</p> <p>Mr Aldo Patriciello, MEP, Italy (video presentation) and Mr Tomislav Sokol, MEP Croatia</p> <p>Prof Jeffrey Lazarus, ISGlobal, Barcelona, Spain*</p> |
| <p>18:20 – 18:30</p> | <p><u>Concluding remarks</u></p> | <p>Prof Heiner Wedemeyer, Co-Chair HepBCPPA and Hannover Medical School, Germany Prof George Papatheodoridis, Co-chair HepBCPPA and University of Athens Medical School, Greece</p> |

* on behalf of **Maria Buti, Angelos Hatzakis, Marko Korenjak, Eberhard Schatz and Heiner Wedemeyer**

Details of breakout sessions – 16:50-17:30

| Timing | Programme Item | Invited Speakers |
|---------------|--|--|
| 16:50 – 17:30 | <p><u>Session 4b. Elements of an effective elimination strategy - Best Practices at the National level (5 BREAKOUT SESSIONS)</u></p> <p>Breakout Session A. ACHIEVE Coalition – Covid-19 lessons learnt for the elimination of viral hepatitis</p> <p>Breakout Session B. National Elimination Plans</p> <p>Breakout Session C. Best practice case studies from Ireland, Greece, Portugal and Montenegro</p> <p>Breakout Session D. Best practice case studies from Spain, Italy, Romania and Egypt</p> | |
| | <p><u>Breakout session A. ACHIEVE Coalition</u> COVID -19 – lessons learnt for the elimination of viral hepatitis</p> <ul style="list-style-type: none"> • <i>Impact of the COVID-19 pandemic on people with hepatitis</i> • <i>Implications for future strategies for testing and treating of hepatitis</i> • <i>The added value of modern technology for better service delivery and data collection</i> • <i>Discussion and Q&A</i> | <p><u>Moderator:</u> Prof David Goldberg, Glasgow Caledonian University, Glasgow, UK.</p> <p>Prof Rui Tato Marinho, Santa Maria Hospital, Medical School of Lisbon, Portugal</p> <p>Dr Philip Bruggmann, Arud Centre for Addiction Medicine, Zurich, Switzerland</p> <p>Prof Mario Poljak, Slovenian HIV/AIDS Reference Centre, University of Ljubljana, Slovenia</p> |
| | <p><u>Breakout session B. National Elimination Plans</u></p> <ul style="list-style-type: none"> • <i>Update on progress in the UK</i> • <i>Update on progress in Italy</i> • <i>Update on progress in Israel</i> • <i>Update on progress in Spain</i> | <p><u>Chair:</u> Dr Zobair Younossi, Inova Health Fairfax Medical Campus, USA</p> <p>Mr Mark Gillyon-Powell, Head of HCV Elimination Programme, NHS England</p> <p>Dr Loreta Kondili Head of HCV Elimination Programme, National Health Institute, Italy</p> <p>Dr Yuval Dadon, HCV National Plan Director, Ministry of Health, Israel</p> <p>Dr Pilar Aparicio Azcárraga, Director of Public Health, Ministry of Health, Spain</p> |

| | | |
|--|--|---|
| | <ul style="list-style-type: none"> • <i>Discussion and Q&A</i> | |
| | <p><u>Breakout session C. Best practice case studies from Ireland, Greece, Portugal and Montenegro</u></p> <ul style="list-style-type: none"> • <i>HepCare Project, Dublin</i> • <i>Aristotle HCV, Athens and Alexandros in Thessaloniki</i> • <i>Microelimination of Hep C virus in severe drug users Mobile Outreach Programme /MOP - Lisbon</i> • <i>PWIDs: harm-reduction and supervised consumption rooms</i> • <i>Discussion and Q&A</i> | <p><i>Chair:</i> Prof Antonio Craxi, University of Palermo, Italy</p> <p>Prof Jack Lambert, Mater Misericordiae Hospital, UCD Medical School, Dublin, Ireland</p> <p>Prof Vana Sypsa, University of Athens Medical School, Greece</p> <p>Dr Rodrigo Coutinho, Ares do Pinhal, Lisbon, Portugal</p> <p>Mr Ivan Vukovic, Mayor of Podgorica, Montenegro</p> |
| | <p><u>Breakout session D. Best practice case studies from Spain, Italy, Romania and Egypt</u></p> <ul style="list-style-type: none"> • <i>Microhepcero Catalonia: SLTC in migrant-vulnerable population</i> • <i>Dual testing of HCV and Covid-19 (ACE)</i> • <i>European-funded Hepatitis screening and diagnostic programme</i> • <i>Egypt: national best practice for HCV elimination</i> • <i>Discussion and Q&A</i> | <p><i>Chair:</i> Prof Laurent Castera, Hôpital Beaujon, University of Paris-VII, France</p> <p>Dr Joan Colom Farran, Catalanian Public Health Agency, Barcelona, Spain</p> <p>Mr Marco Bartoli, EpaC Onlus, Italy</p> <p>Prof Cora Pop, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania</p> <p>Prof Gamal Esmat, University of Cairo, Egypt</p> |

Official Partners

ACHIEVE

ASSOCIATIONS COLLABORATING ON HEPATITIS TO
IMMUNIZE AND ELIMINATE THE VIRUSES IN EUROPE

AEHVE

Alianza para la Eliminación de las
Hepatitis Viricas en España



Correlation
European
Harm Reduction
Network

EATG

European
AIDS Treatment
Group



EASL

ENDORSED
EVENT

The Home of Hepatology



ELPA
European Liver
Patients' Association



INTERNATIONAL CENTRE FOR MIGRATION, HEALTH AND DEVELOPMENT

UNIT2

Global Parliamentarians Network
to End Infectious Diseases



**Liver
Patients**
International



VHPB

Financial Support

abbvie



GILEAD

This event has been supported by grants from AbbVie and Gilead Sciences Ltd Europe